NCT03961659 is a NA clinical trial of Liraglutid in Type 2 Diabetes Mellitus, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.

What drugs are being tested in NCT03961659?

Interventions in NCT03961659: Liraglutid, Dapagliflozin, Acarbose.

What condition does NCT03961659 study?

NCT03961659 studies Type 2 Diabetes Mellitus, Obesity, Cognitive Impairment.

Is NCT03961659 still recruiting?

NCT03961659 is currently status unknown. Last updated 22 May 2019.

Last reviewed 2019-05-22 · How we verify

NCT03961659

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective, Randomized, Open Label, Parallel, 16-week Study to Explore and Evaluate the Therapeutic Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese Patients With T2DM Inadequately Controlled With Metformin Monotherapy.

Status unknown NA Last updated 22 May 2019

What this trial tests

NA trial testing Liraglutid in Type 2 Diabetes Mellitus in 87 participants. Status unknown.

Timeline

1 May 2019

Primary endpoint
1 August 2020

1 February 2021

Quick facts

Lead sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	87
Start date	1 May 2019
Primary completion	1 August 2020
Estimated completion	1 February 2021
Sites	1 location across China

Drugs / interventions tested

Liraglutid — full drug profile →
Dapagliflozin (DAPAGLIFLOZIN) — full drug profile →
Acarbose (ACARBOSE) — full drug profile →

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Obesity — all drugs for Obesity →
Cognitive Impairment — all drugs for Cognitive Impairment →

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Who can join

Adults 40 to 75, any sex, with Type 2 Diabetes Mellitus or Obesity. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change of olfactory brain activation by fMRI
Time frame: from baseline to 16 weeks' follow-up.
Compare the change of olfactory brain activation by fMRI from baseline to 16 weeks' follow-up

Sponsor's own description

This is a prospective, randomized, open label, parallel, 16-week study to explore and evaluate the therapeutic effects of liraglutid, dapagliflozin and acarbose on the cognitive function, olfactory function, and odor-induced brain activation in overweight/obese patients with type 2 diabetes mellitus(T2DM) inadequately controlled with metformin monotherapy.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer's Disease.
Toniolo S, Sen A, Husain M. · · 2020 · cited 74× · PMID 33297460 · DOI 10.3390/ijms21239318
Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease.
Hong CT, Chen JH, Hu CJ. · · 2024 · cited 35× · PMID 39501255 · DOI 10.1186/s12929-024-01090-x
Repositioning of Anti-Diabetic Drugs against Dementia: Insight from Molecular Perspectives to Clinical Trials.
Mantik KEK, Kim S, Gu B, Moon S, et al · · 2023 · cited 16× · PMID 37511207 · DOI 10.3390/ijms241411450
Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus.
Dou X, Zhao L, Li J, Jiang Y. · · 2025 · cited 4× · PMID 40171533 · DOI 10.3389/fnins.2025.1537898
Dapagliflozin restores odour-induced functional integration of primary olfactory cortex circuit but not olfactory-related regional brain activation in patients with type 2 diabetes: A 16-week randomised comparative study.
Li X, Zhang Y, Bi Y, Lu J, et al · · 2025 · cited 1× · PMID 40954925 · DOI 10.1111/dom.70132

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials

Trials by the same sponsor.

NCT06966765 — Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute D · Phase 3 · not yet recruiting
NCT07403071 — Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Expe · not yet recruiting
NCT07532538 — A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions · not yet recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07399574 — Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diqua · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03961659 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Last refreshed: 22 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03961659.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing